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Cachexia, or body wasting,1 is a serious complication and
frequently occurs at advanced stage of the variety of chronic
diseases, including cancer, multiple inﬂammatory organ-spe-
ciﬁc disease, and cardiovascular disease. Cachexia affects
the life quality and survival of the patients.2,3 The prevalence
of cachexia depends on the underlying disease and widely
ranges between 15 and 90%.4 Patients with cancer are most
commonly affected by cachexia that often occurs as a late-
stage complication. In cancer, the prevalence of cachexia5
may vary between 50 and 90% depending on the type of
cancer,6 where a clinical course of gastrointestinal or lung
cancers is most frequently associated with the development
of cachexia.7,8 The multifactorial pathogenesis of cachexia,
including anorexia, inﬂammatory activation, and impaired
metabolic turnover of both structural and energy metabo-
lism, lead to a decrease of adipose and lean tissue mass
and low muscle strength.9
The discussion is ongoing whether cachexia in various
chronic diseases should be viewed as a common ﬁnal meta-
bolic pathway regardless of the underlying disease or if it is
disease speciﬁc, and distinct pathophysiological mechanisms
exist in different diseases. A recent retrospective clinical
study described different phenotypes of cachexia in patients
with advanced pancreatic ductal adenocarcinoma (PDAC)
undergoing chemotherapy.10 The assessment of longitudinal
changes of body composition by computed tomography
(CT) revealed three phenotypes of body wasting in these
patients: patients who lost skeletal muscle and fat tissue,
patients who only lost fat tissue, and patients without
wasting who had a signiﬁcantly improved survival. Several
other studies investigated patients with different types of
gastrointestinal cancer and reported either a loss of muscle
tissue11,12 or a loss of both skeletal muscle and adipose tissue
mass.13 In addition, loss of cardiac muscle tissue in cancer
cachexia (CC) has been shown in clinical and experimental
studies.14–16
It is known that cachexia is characterized by body wasting
that involves all compartments of body tissue (i.e. muscle,
adipose, and bone tissues).9,17,18 From all of these compart-
ments, the loss of muscle tissue is considered the key
pathophysiological mechanism to explain reduced physical
capacity, increased frailty, susceptibility to disease progres-
sion, increased hospitalization rate, and, consequently,
increased mortality. A major hurdle for the research on loss
of muscle tissue, or sarcopenia,19,20 is a lack of the reference
standard for determination of skeletal muscle mass.21,22 A
number of clinical diagnostic methods are available ranging
from easy applicable, such as bioelectrical impedance
analysis (BIA),23,24 to highly complex, challenging, and costly
techniques, such as magnetic resonance imaging (MRI) or
CT.25,26 The setting of the research question and speciﬁc
study design deﬁne the appropriate method to be used for
the given context. Importantly, apart from the assessment
of muscle bulk, functional and metabolic characteristics of
the skeletal muscle tissue might have a role in the determina-
tion of functional capacity and symptomatic severity of
muscle wasting and hence may have an impact on clinical
outcome.27–30
As previously mentioned, cachexia is usually reported as a
complication of chronic diseases, including chronic obstruc-
tive pulmonary disease (COPD),31,32 rheumatoid arthritis,33,34
chronic hepatitis and cirrhosis,35,36 diabetes mellitus,37
chronic kidney disease (CKD),38 and chronic heart failure
(CHF).39–41 A hypothesis has been proposed that independent
of the individual chronic disease, the wasting process follows
a common ﬁnal metabolic pattern. This metabolic pattern
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usually relates to an advanced stage of the underlying disease
and can best be summarized as an increased catabolic
turnover and anabolic blunting.
Nevertheless, cachexia has not been sufﬁciently investi-
gated in many other pathological conditions, including stroke.
Body weight loss after neurological stroke is frequently
observed in clinical and experimental settings and associated
with adverse clinical outcome.42,43 The consequences of
ischaemic stroke on myocardium have been investigated in
an experimental study by Veltkamp et al.,44 which showed a
transient myocardial dysfunction and atrophy of cardio-
myocytes following the brain ischaemia. Further clinical
studies investigating cachexia and muscle wasting in patients
with stroke are warranted.
Despite intensiﬁed research in the ﬁeld, no medical
therapy has emerged for a wider clinical application to
prevent or even reverse the development of cachexia and
muscle wasting. The medical treatment of cachexia includes
a dietary supplementation of proteins, vitamins, or min-
erals.45–48 Multiple attempts have been made to identify
and validate treatment options to counteract the develop-
ment of muscle wasting. The efﬁcacy of physical exercise
training has been conﬁrmed in clinical and experimental stud-
ies, and it is regarded as the most promising treatment ap-
proach to delay or prevent progression of muscle
wasting.49–53 However, there is an urgent need for the
development of clinical practice guidelines for treatment
patients with cachexia.54 Additional clinical studies are highly
warranted to explore further the mechanisms of tissue
wasting in chronic illnesses and to discover novel drug
therapies to prevent or reverse the development of cachexia
regarded as a severe complication of a variety of end-stage
chronic disease.
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